MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Proceeds from issuance ofcommon stock and...$164,089K Proceeds from sales ofcommon stock, pursuant...$290K Net cash provided byfinancing activities$164,364K Canceled cashflow$15K Net increase(decrease) in cash and cash...$23,343K Canceled cashflow$141,021K Repayment of note payable$15K Maturities ofavailable-for-sale securities$47,641K Share-based compensation$2,553K Depreciation andamortization expense$1,126K Other noncash income,net-$78K Other noncurrentliabilities$51K Net cash used ininvesting activities-$109,553K Net cash used inoperating activities-$31,468K Canceled cashflow$47,641K Canceled cashflow$3,808K Purchases ofavailable-for-sale securities$150,336K Net loss-$26,189K Accounts payable andaccrued expenses-$4,213K Accrued personnelexpenses-$3,613K Additions to property andequipment$6,858K Net accretion ofdiscounts on...-$490K Interest receivable$392K Prepaid expenses andother current assets$327K Accounts receivable$52K
Cash Flow

Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics, Inc. (CATX)

source: myfinsight.com